BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » The Fastest Growing #StemCell Account on Twitter
Stem Cell Data on Twitter

The Fastest Growing #StemCell Account on Twitter

October 26, 2015 By Cade Hildreth (CEO) Leave a Comment

Recently, we made an important decision. We committed to being a fast, accurate, and fascinating provider of stem cell and cord blood industry news on Twitter. The decision was inspired by an article I read that which identified that increasing numbers of people are now using social media as a news source, gradually replacing traditional news outlets such as TV and newspapers.

Discover class-defining bioproduction tools.

Since that decision three months ago, BioInformant’s Twitter following has jumped to over 3,000 followers.

Most impressively, we have received 2,726 organic followers over the past 90 days, making us the fastest growing stem cell account on Twitter!

bitbio
BioInformant - Fastet Growing Stem Cell Account on Twitter
Note: Click to enlarge image.

A few existing influencers have given me a bit of “push back,” but all-in-all, the outpouring of support and appreciation for this effort has been incredible.

As most of you know, BioInformant was the first and remains the only market research firm to specialize in the stem cell industry, so we use our social media platforms to give away an incredible amount of free research.

Pluristyx

Thank you to all of the stem cell and cord blood enthusiasts who have shown support. I thank you for trusting us as a source of information. Want to follow us for #stemcell and #cordblood industry news?

Click here: https://twitter.com/StemCellMarket

 

iPSC-derived cardiomyocte therapy
Rate this post

Filed Under: Cord Blood, Stem Cells Tagged With: cord blood, influencer, social media, stem cells, twitter

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Cord Blood Market Segmentation

Cord Blood Market Segmentation – Biobanking, HSCT, Cellular Therapy, Genetic Manipulation, & Research Tools

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.